Pharma Clinical S.A.G (2003) Ltd. ads

Running a biomarker-selected, complex, or early-phase oncology program? Meet us at ESMO 2026. Pharma Clinical manages the full pathway from feasibility to enrolment: regulatory execution, site activation, molecular-testing logistics, and specialised centre selection. 35 years. 300+ studies. We work with leading oncology centres including Sheba (ranked #7 globally, Newsweek/Statista 2026), Rambam, Tel Aviv Sourasky and others - with access to a genetically diverse population and established hereditary-cancer screening infrastructure, well suited for DDR, BRCA, and HRD-focused programs. We build the country case, protocol by protocol. Nathan Stolero, CEO, is available for feasibility meetings during the conference. Meet us at ESMO 2026 | Madrid, Oct 23-27 Click Below to Book a Meeting >>

Global Execution. Local Israel Management. Taking your clinical trial overseas shouldn’t mean losing direct sight of your study. You don’t need more middle management-you need direct communication and execution you can rely on. With Pharma Clinical, you get the best of both worlds: 🔹 Israeli Management & Mindset: Keep project leadership with a team that speaks your language and moves at your speed. 🔹 Proven Overseas Resources: Tap into established international connections, infrastructure, and site networks that are already up and running. 🔹 Zero Friction: One single point of contact in Israel for your entire global study. Backed by 35+ years of clinical expertise and over 300+ studies managed, we ensure your trial stays on track, on budget, and fully transparent. Ready to expand your clinical trials abroad? Let’s map your route together.

Advancing Vision Care: Where Genetic Research Meets Clinical Reality Ophthalmology is entering a particularly exciting period. Gene therapies, molecular interventions and new treatment pathways are creating possibilities for retinal diseases that, until recently, had very limited treatment options. Together with Prof. Omer Trivizki, we are looking at some of the developments changing how these conditions are studied and treated. “Working both in the clinic and in research makes it very clear that innovation cannot remain theoretical. It has to reach patients, answer clinically relevant questions and be tested in a way that reflects the realities of everyday ophthalmic care.” 🔹 Genetic therapies are being developed to address the underlying biological cause of retinal degeneration, rather than treating only its consequences. 🔹 New molecular approaches are being investigated to protect retinal tissue and blood vessels from damage caused by diseases such as diabetes and age-related macular degeneration. 🔹 The number and complexity of ophthalmic clinical trials continue to grow, including early-phase studies evaluating entirely new mechanisms of action and delivery methods. From Prof. Trivizki’s perspective, the real challenge is no longer only developing innovative treatments. It is translating them into well-designed clinical trials, selecting the right patients, identifying meaningful imaging and functional endpoints, and ultimately determining whether scientific promise leads to a genuine benefit for patients. Having collaborated with Prof. Trivizki on several such innovative studies, Pharma Clinical has found that strong local clinical expertise and operational execution can make the difference between a promising concept and a trial that successfully moves forward. Innovation is not only about what may become possible in the future. It is also about building the clinical infrastructure needed to evaluate these treatments today. Learn how Pharma Clinical supports ophthalmic clinical research >>

Running a biomarker-selected, complex, or early-phase oncology program? Meet us at ESMO 2026. Pharma Clinical manages the full pathway from feasibility to enrolment: regulatory execution, site activation, molecular-testing logistics, and specialised centre selection. 35 years. 300+ studies. We work with leading oncology centres including Sheba (ranked #7 globally, Newsweek/Statista 2026), Rambam, Tel Aviv Sourasky and others - with access to a genetically diverse population and established hereditary-cancer screening infrastructure, well suited for DDR, BRCA, and HRD-focused programs. We build the country case, protocol by protocol. Nathan Stolero, CEO, is available for feasibility meetings during the conference. Meet us at ESMO 2026 | Madrid, Oct 23-27 Book a Meeting >>

Looking to run clinical trials in Israel but don't have a local presence? Without an on-the-ground partner, navigating Israel's clinical landscape can be challenging - from regulatory requirements to investigator relationships and site-level operations. Here's what partnering with Pharma Clinical gives you: 🔹 Direct access to leading investigators and research sites across Israel - no need to build local relationships from scratch. 🔹 Deep familiarity with local regulatory authorities and approval timelines. 🔹 Faster site startup, fewer operational surprises, and real-time problem solving. 🔹 A trusted local partner with 35+ years of experience, working as a seamless extension of your team. Ready to establish your clinical presence in Israel? Contact us today >

Looking to run clinical trials in Israel but don't have a local presence? Without an on-the-ground partner, navigating Israel's clinical landscape can be challenging - from regulatory requirements to investigator relationships and site-level operations. Here's what partnering with Pharma Clinical gives you: 🔹 Direct access to leading investigators and research sites across Israel - no need to build local relationships from scratch. 🔹 Deep familiarity with local regulatory authorities and approval timelines. 🔹 Faster site startup, fewer operational surprises, and real-time problem solving. 🔹 A trusted local partner with 35+ years of experience, working as a seamless extension of your team. Ready to establish your clinical presence in Israel? Contact us today >